MS Connection Blog


When Genes and the Environment Collide

Blog Summary

What happens when genes and the environment interact? This question is one of the complex pieces of the MS puzzle. More than 200 MS susceptibility genes have been identified, and the list of environmental factors linked to MS is slowly coming into focus. Of course, it’s important to remember that not everyone who develops MS has been exposed to the identified MS risk factors, and people exposed to those factors won’t necessarily develop MS. But how do genetic and environmental triggers interact to bring on MS, or make it worse? Several presentations at last week’s ACTRIMS 2017 meeting addressed these important gaps in our knowledge...

Progressive MS at ECTRIMS: New Directions and Challenges

Blog Summary

Greetings from the second full day of the ECTRIMS2016 conference in London. Today was packed with research presentations and poster sessions, all about MS.    There are many different topics being covered at this meeting, and I’d like to focus this blog on one I’m particularly passionate about, progressive MS. A press conference yesterday hosted by the International Progressive MS Alliance, which I help lead, announced new investments of over $14 million US dollars to support three Collaborative Network Awards. These international teams were selected to accelerate the pace of research in key areas... 

Progressive MS: Looking for answers NOW

Blog Summary

People who live with progressive MS have many questions, but one I hear often is, “When will there be treatment options for me?” Based on what I saw and heard at last week’s AAN, I’m pleased to report that researchers from around the world are making important progress toward treatments and therapies for people living with progressive MS. Several groups presented results or updates from large, ongoing studies involving people living with primary-progressive MS: one, a study of oral laquinimod, an experimental immunomodulator,  in 375 people with primary-progressive MS which recently began recruitment ; second, a clinical trial of oral ibudilast, an anti-inflammatory enzyme used in Japan, recruiting 250 people with primary- or secondary-progressive MS; and third, a study of ocrelizumab – an antibody cousin of rituximab delivered by infusion – in 740 people with primary-progressive MS that has completed enrollment. No results are available yet, but some should be next year, and it’s encouraging to see that these trials are getting under way. I hope the findings provide us with new treatment approaches for people with progressive MS. (Abstracts # P7.210, P7.017) ...